Editorial commentaries

1063 Ion channel disorders: still a fascinating topic—news on episodic ataxia type 1
M Strupp

1064 Glycosylation defects as an emerging novel cause leading to a limb-girdle type of congenital myasthenic syndromes
K Ohno

1065 Natalizumab-induced PML: can the beast be tamed?
R Hofheld

1066 Sunshine and multiple sclerosis
B V Taylor

1067 The problem of non-superiority: what do we know after KOMET?
A C Sønne-Sørensen

Multiple sclerosis

1068 Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
S Dahlhaus, R Hoepner, A Chan, I Kleiter, O Adams, C Lukas, K Hellwig, R Gold

1075 Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis
R Zivadinov, C N Tread, B Weinstock-Guttman, C Turner, N Bergslund, K O’Connor, M G Dwyer, E Carl, D P Ramasamy, J Qu, M Ramanathan

1082 Brain atrophy and lesion load predict long-term disability in multiple sclerosis

1092 A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis
S Thomas, P W Thomas, P Kersten, R Jones, C Green, A Nock, V Slingsby, A D Smith, R Baker, K T Galvin, C Hilliar

Movement disorders

1100 Primary progressive multiple sclerosis: progression and challenges
C M Rice, D Cotrell, A Wilkins, N J Scoling

1107 Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1
S E Tomblinson, S Rajakulendran, S V Tan, T D Graves, D-E Bamiou, R W Labrum, D Burke, C M Sue, P Giunti, S Schorge, D M Kullmann, M G Hanna

1113 Suicide ideation and behaviours after STN and GPI DBS surgery for Parkinson’s disease: results from a randomised, controlled trial
D Weintraub, J E Duda, K Carlson, P Luo, O Saghier, M Stern, K A Follett, D Reda, F M Weaver, for the CSP 468 Study Group

Neuromuscular

1119 Clinical features of congenital myasthenic syndrome due to mutations in DPA1/G
S Finlayson, J Palace, K Belaya, T J Walls, F Norwood, G Burke, J L Holton, S I Pascual-Pascual, J Cosins, D Beeson

Cognition

1126 HIV, dementia and antiretroviral drugs: 30 years of an epidemic
H Manzi, H R Jäger, A Winston
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuropsychiatry</td>
<td>1138</td>
<td>KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy</td>
<td>E Trinka, A G Marson, W Van Paesschen, R Kälviäinen, J Marovac, B Duncan, S Boyle, Y Hallström, P Hon, G C Muscas, M Newton, H-J Meencke, P E Smith, B Pohlmann-Eden, for the KOMET Study Group</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>1150</td>
<td>Long term (13 years) prognosis after primary intracerebral haemorrhage: a prospective population based study of long term mortality, prognostic factors and causes of death</td>
<td>B M Hansen, O G Nilsson, H Andersson, B Norving, H Säveland, A Lindgren</td>
</tr>
<tr>
<td>Neurodegeneration</td>
<td>1156</td>
<td>Prevalence of adult Huntington’s disease in the UK based on diagnoses recorded in general practice records</td>
<td>S J W Evans, I Douglas, M D Rawlins, N S Wexler, S J Tabrizi, L Smeeth</td>
</tr>
<tr>
<td>Neurodegeneration</td>
<td>1136</td>
<td>Periventricular heterotopia in refractory epilepsy</td>
<td>A C Christopher, K Koshy</td>
</tr>
<tr>
<td>Neuroinfection</td>
<td>1148</td>
<td>Successful outcome after traumatic rupture and secondary thrombosis of the superior sagittal sinus</td>
<td>E A Oudeman, P C De Witt Hamer</td>
</tr>
<tr>
<td>Neurological pictures</td>
<td>1176</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PostScript</td>
<td>1180</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>